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Summary
The chromosomal translocation t(12;21) resulting in the ETV6/RUNX1
fusion gene is the most frequent structural cytogenetic abnormality among
patients with childhood acute lymphoblastic leukaemia (ALL). We investi-
gated 62 ETV6/RUNX1-positive childhood ALL patients by single nucleo-
tide polymorphism array to explore acquired copy number alterations
(CNAs) at diagnosis. The mean number of CNAs was 2·82 (range 0–14).
Concordance with available G-band karyotyping and comparative genomic
hybridization was 93%. Based on three major protein-protein complexes
disrupted by these CNAs, patients could be categorized into four distinct
subgroups, defined by different underlying biological mechanisms relevant
to the aetiology of childhood ALL. When recurrent CNAs were evaluated
by an oncogenetic tree analysis classifying their sequential order, the most
common genetic aberrations (deletions of 6q, 9p, 13q and X, and gains of
10 and 21) seemed independent of each other. Finally, we identified the
most common regions with recurrent gains and losses, which comprise
microRNA clusters with known oncogenic or tumour-suppressive roles.
The present study sheds further light on the genetic diversity of ETV6/
RUNX1-positive childhood ALL, which may be important for understand-
ing poor responses among this otherwise highly curable subset of ALL and
lead to novel targeted treatment strategies.
Keywords: childhood acute lymphoblastic leukaemia, ETV6/RUNX1 trans-
location, genome-wide screening.
Acute lymphoblastic leukaemia (ALL) is the most common
cancer in children (Hjalgrim et al, 2003). In B-lineage child-
hood ALL the most frequent structural cytogenetic abnor-
mality, present in 25% of the cases, is the chromosomal
translocation t(12;21)(p13;q22) resulting in the ETV6/
RUNX1 fusion gene (Shurtleff et al, 1995; Forestier et al,
2008). The event-free survival (EFS) of childhood ALL
patients after first line therapy is approximately 80% (Schmi-
egelow et al, 2010), however presence of the ETV6/RUNX1
fusion gene is generally associated with a more favourable
prognosis, with an EFS of approximately 90% (Forestier
et al, 2008). The ETV6/RUNX1 fusion gene is believed to
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represent an initiating event in the development of this
childhood ALL subset. This initiating event, seen as early as
in utero (Wiemels et al, 1999; Hjalgrim et al, 2002), most
likely requires additional genetic changes in order to lead to
leukaemia e.g. ETV6/RUNX1 transcripts have been demon-
strated in normal cord blood samples at low levels (Mori
et al, 2002; Lausten-Thomsen et al, 2011) and neither ETV6/
RUNX1-positive knock-in mouse models nor carriers of
ETV6/RUNX1-positive pre-leukaemic cells will all develop
leukaemia (Fischer et al, 2005; Hong et al, 2008). Thus, the
development of ETV6/RUNX1-positive leukaemia requires
one or more secondary genetic changes and previous studies
have indeed shown additional genetic changes in the majority
of ETV6/RUNX1-positive childhood ALL patients (Forestier
et al, 2007; Mullighan et al, 2007; Kawamata et al, 2008; Lil-
ljebjorn et al, 2007, 2010; Parker et al, 2008; Mullighan et al,
2008; van Delft et al, 2011).
In the present study, we applied high-resolution Affyme-
trix GeneChip® 500K profiling to 62 ETV6/RUNX1-positive
childhood ALL patients to explore in detail copy number
alterations (CNAs) throughout the genome. Furthermore, we
investigated the inter-dependencies of the recurrent CNAs
and involvement in protein-protein complexes among them,
and correlated the CNAs with biologically relevant microR-
NAs (miRNAs) affected by the aberrations.
Methods and materials
Patients
The ETV6/RUNX1-positive childhood ALL patients (aged
between 1 and 15 years at the time of diagnosis) from Den-
mark, Norway, Sweden and Iceland were diagnosed and
enrolled in the Nordic Society for Paediatric Haematology
and Oncology (NOPHO) treatment protocols (NOHPO
ALL-92 or NOPHO ALL-2000) (Schmiegelow et al, 2010). A
total of 133 patients were found to be positive for ETV6/
RUNX1 by fluorescent in situ hybridization (FISH) and/or
reverse transcription polymerase chain reaction (RT-PCR) by
routine investigation from 1996–2007, and diagnostic
tumour DNA samples were available for 99 of these patients.
Ten samples were of poor quality and/or had insufficient
amount of DNA to be analysed and of the remaining sam-
ples, 62 fulfilled the quality criteria (QC) for inclusion in the
bioinformatics analyses (Table 1). The study was approved
by The Capital Region of Denmark Committee on Biomedi-
cal Research Ethics and The Danish Data Protection Agency.
G-band karyotyping and comparative genomic
hybridization
G-band karyotyping was performed as part of the routine
investigation on short-term cultured leukaemic cells by stan-
dard techniques. As part of a separate study, high-resolution
comparative genomic hybridization (CGH) was performed
for a subset of the patients (Kristensen et al, 2003). G-band
karyotyping and/or CGH data was available in 54 (87·1%) of
the included cases (Table S1).
Single nucleotide polymorphism (SNP) array analysis
DNA from bone marrow or blood samples acquired at diag-
nosis was extracted and purified by sodium chloride and eth-
anol precipitation. For SNP array analysis the DNA was
processed and hybridized to Affymetrix GeneChip® Mapping
500K array set according to the manufacturer’s instructions
(Affymetrix, Santa Clara, CA, USA). The Affymetrix Gene-
Chip® Mapping 500K array set comprises two arrays and is
processed by two assay kits differing only in the restriction
enzyme used (Affymetrix GeneChip® Mapping 250K Nsp
Assay Kit and Affymetrix GeneChip® Mapping 250K Sty
Assay Kit). Briefly, 250 ng DNA was digested by either Nsp I
or Sty I, followed by ligation of adaptors, allowing PCR
amplification of fragments in sizes from 200 to 1100 bp.
PCR products were fragmented and end-labelled with biotin.
Samples were subsequently hybridized to the arrays. The
Table 1. Patient characteristics and copy number alterations.
Characteristics Patients
Gender
Male 37 (59·7%)
Female 25 (40·3%)
Age, years, median (range) 4·17 (1·30–15)
WBC, 9109/l, median (range) 11·5 (0·80–110)
Risk group
SR 28 (45·2%)
IR 23 (37·1%)
HR 11 (17·7%)
Treatment protocol
NOPHO ALL-92 33 (53·2%)
NOPHO ALL-2000 29 (46·8%)
Events
Induction failure 0 (0%)
Resistant disease 0 (0%)
Relapse 4 (6·5%)
Death in remission 0 (0%)
Secondary malignancy 0 (0%)
Total events 4 (6·5%)
EFS 93·5%
CNA (mean)
Gains > 1 Mb 0·73 (0–8)
Gains < 1 Mb 0·02 (0–1)
Losses > 1 Mb 1·24 (0–8)
Losses < 1 Mb 0·85 (0–6)
Total > 1 Mb 1·97 (0–9)
Total < 1 Mb 0·85 (0–6)
Total 2·82 (0–14)
WBC, white blood cell count; SR, standard risk; IR, intermediate
risk; HR, high risk; NOPHO, Nordic Society for Paediatric Haema-
tology and Oncology; EFS, event-free survival; CNA, copy number
alteration; Mb, megabase.
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arrays were washed and stained with phycoerythrin-conju-
gated streptavidin (SAPE) using the Affymetrix Fluidics Sta-
tion® 450 and were scanned in the Affymetrix GeneChip®
2500 scanner to generate fluorescent images, as described in
the Affymetrix GeneChip® protocol. Cell intensity files (CEL
files) were generated in the GeneChip® operating software
(GCOS) version 5.0.
Data processing
The signal intensity data based on the raw CEL files was gen-
erated using the Affymetrix Power Tools (APT) Software
Package. First, for each array a QC call rate was generated
using the Dynamic Model algorithm (Di et al, 2005).
According to the manufacturer’s recommendations, only
samples achieving call rates  93% were used for further
analysis. For the 62 samples and 200 controls fulfilling QC,
genotype calls were generated using the BRLMM algorithm
(http://array.mc.vanderbilt.edu/microarray/dna/brlmm.pdf).
Allele-specific signals were extracted from median polish
summarized and quantile normalized Perfect Match (PM)
probe-intensity values. The R-GADA package (Pique-Regi
et al, 2010) was employed to detect the recurrent CNAs. The
package implements a segmentation algorithm to call CNAs
based on genome alternation detection analysis (GADA).
During the segmentation procedure the parameters control-
ling the trade-off between the sensitivity and false discovery
rate (FDR) were set to achieve high specificity at the cost of
sensitivity. The minimum segment length required for classi-
fication as a CNA was 8 probes, in order to exclude detec-
tion of false alterations due to extreme outliers. The 200
controls were used to exclude alterations representing the
normal CNAs. Final estimation of copy number states was
verified by visual examination.
Data visualization and biological correlations
The display of all the CNAs in circos format was done accord-
ing to Krzywinski et al (2009). Recurrent CNAs were defined
as gains or deletions of material occurring in the same region
in at least two patients and plotted as a heatmap (Fig S1). The
recurrent CNAs were then analysed further with a CRAN R
package Oncotree 0·31 to determine a tree model for oncogen-
esis (Desper et al, 1999; Szabo & Boucher, 2002).
To explore functional modules that are potentially affected
by the CNAs, enrichment analysis on protein-protein interac-
tion complexes was performed using custom written Perl
scripts. Only patients with losses of genetic material were
included in this analysis, as these are likely to result in a
direct loss of function and hence are most disruptive to the
complexes. Using a curated collection of protein-protein
complexes (Lage et al, 2007), we defined a set of complexes
that categorized the patients into distinct subgroups defined
by different underlying biological mechanisms. All combina-
tions of 2–5 protein-protein complexes were tested to find a
set of complexes representing the largest possible group of
patients with the smallest possible overlap between different
complexes. From the final collection of complex sets that
best fulfilled the criteria, only those that comprised of genes
highly expressed in B lymphoblasts were selected and priori-
tized according to leukaemia-related annotations among Bio-
Alma terms assigned to the complexes. The miRNA
annotations were based on miRBase version 16 (Griffiths-
Jones, 2010) while their experimentally validated target infor-
mation was collected from miRecords and miRWalk databas-
es (Xiao et al, 2009; Dweep et al, 2011).
Results
Genomic profiling of ETV6/RUNX1-positive childhood
ALL patients
The SNP array analysis revealed a total of 174 CNAs (30
were recurrent) among the 62 successfully analysed cases
(whole chromosome deletions and amplifications each
counted as one cytogenetic change). Of these, 129 were dele-
tions, 77 above 1 Mb (including two whole X chromosome
deletions), and 52 focal deletions below 1 Mb. A total of 45
gains were detected, of which 44 were above 1 Mb (including
18 whole chromosome gains), and only one focal amplifica-
tion below 1 Mb (Fig 1 and Table S1). Since the 500K arrays
do not have any probes covering the p arms of chromosomes
13, 14, 15, 21 and 22, some large amplifications of these
chromosomes may actually be trisomies. The mean number
of CNAs per patient was 2·82 (range 0 –14) and 13 cases
(21%) did not display any CNAs (Table 1 and Table S1).
Concordance between G-band karyotyping and/or CGH
and the SNP array analysis data was 93%. Thus, in 51 of the
54 cases with available data, the SNP array results either con-
firmed and/or added to G-band karyotyping and/or CGH
(Table S1). As summarized in Fig 1, all but chromosome 17
demonstrated CNAs above 1 Mb. If focal lesions are
included, all chromosomes demonstrated alterations. The
most common CNAs above 1 Mb involved deletions of 12p
(39%), 6q (13%), 9p (10%), 11q (10%), 13q (10%), 8p (8%)
and amplifications of Xq (11%) (one female and six males),
21 (10%), 10 (5%) and Xp (5%) (two females and one
male). Of the focal changes, the most common included
deletions in 14q32·33 (21%), 7p14·1 (18%), 22q11·22 (13%),
14q11·2 (8%) and 7q34 (6%).
Biological correlations
Overall, neither individual aberrations nor heatmap clustering
of the recurrent aberrations (Fig S1) correlated significantly
with age or white blood cell count (WBC). In an attempt to
classify the patients more distinctively, a systems biology
approach was applied investigating the likely effects of losses
of genetic material at the protein complex level. Grouping of
patients in this way reflects more closely the clinical parame-
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ters and suggests different potential biological mechanisms
underlying the leukaemogenesis (Data S1, Fig S2).
Next, the inter-dependency of the recurrent CNAs was
investigated by an oncogenetic tree analysis to explore the
sequential order of CNAs as previously done by Lilljebjorn
et al (2010). By this approach, deletions of 12p, 14q32 and
gain of 21q were classified as early events, i.e. being close to
the root and acting as new roots of their own subtree
(Fig 2). Importantly, even though gain of 12p (the most
common additional aberration) was close to the root, it did
not seem to be a required precursor for other changes.
Furthermore, the most common aberrations in ETV6/
RUNX1-positive patients (deletions of 6q, 9p, 12p, 13q, and
X, and chromosome 10 and 21 amplifications) (Forestier
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Fig 1. The recurrent cytogenetic alterations in ETV6/RUNX1 patients plotted in Circos format (Krzywinski et al, 2009). The chromosomes are
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et al, 2007), seemed independent of each other, i.e. the
occurrence of one did not change the likelihood of occur-
rence of the others. Still, 9p deletions seemed to precede 8p
deletions and chromosome X deletions were rooted in 8p
deletion according to the oncogenetic branching model
(Fig 2). The reported estimated false-positive error rate was
0·0007 and the false-negative error rate was 0·30.
Finally, regions undergoing recurrent aberrations in the
patients were also investigated for transcribed miRNAs. miR-
NAs can regulate protein-coding gene targets, thus they may
play an oncogenic or tumour suppressive role, depending on
their transcription levels, DNAmethylation and CpG content of
the surrounding regions, mutations and the genes they regulate
(Data S2). The most frequently deleted regions, containing
important miRNA clusters, were on 11q and 13q, while the most
frequently amplified regions were on chromosomes 21 and X,
comprising other miRNA clusters (Data S2 and Table S2).
Discussion
The present study sheds further light on the genetic diversity
of ETV6/RUNX1-positive childhood ALL. Overall, the mean
number of alterations per patient (2·82, range 0–14) is in
agreement with previous studies of ETV6/RUNX1-positive
childhood ALL patients (Forestier et al, 2007; Mullighan
et al, 2007; Parker et al, 2008; Lilljebjorn et al, 2010; van
Delft et al, 2011). Higher specificity was prioritized in
attempt to reduce the rate of false positive findings, at the
cost of reduced sensitivity, especially with regard to detection
of focal aberrations. Furthermore, due to the size of the
study, some recurrent changes may have been missed if they
did not occur in at least two patients. On the other hand,
the strict criteria increased the reliability of the oncogenetic
tree and systems biology analyses, and is furthermore sup-
ported by the high concordance with previous results of G-
band karyotyping and CGH analyses. The larger alterations:
12p, 6q, 9p, 11q, 13q and gains of chromosome 21 and Xq
occurred in at least 10% of the patients, supporting previous
reports (Forestier et al, 2007; Mullighan et al, 2007; Kawa-
mata et al, 2008; Lilljebjorn et al, 2007, 2010; Parker et al,
2008; Mullighan et al, 2008; van Delft et al, 2011). Moreover,
gain of Xq is far more common in males than in females,
which supports the previous findings of Lilljebjorn et al
(2007); (Lilljebjorn et al, 2010) and could imply loss of X
chromosome silencing of that specific region in females lead-
ing to similar gene dosage effects in both sexes. The affected
gene(s) remains to be determined.
Importantly, these non-random aberrations should be
interpreted by their putative biological consequence. Here we
proposed an alternative grouping of patients based on inte-
grative analysis of recurrent CNAs and involved protein-pro-
tein interaction complexes, which may suggest different
underlying biological mechanisms. This classification reflects
that deletions of different genes, often from different chro-
mosomes, may lead to disruption of the same complex
resulting in a similar phenotype. In most cases the loss of a
gene, evidenced through CNAs, leads to perturbation of
interaction with another gene with high connectivity in the
complex, and therefore is likely to have a functional effect.
To speculate on the relationship and order by which these
CNAs occur, we used a branching oncogenetic tree model.
The model identified deletions on 12p, 14q32 and gain of
Fig 2. Oncogenetic tree. A probabilistic model of the sequential order of acquiring of the copy number alterations. The root of the tree represents
the initial event - the t(12;21) chromosomal translocation. The numbers at each edge indicate the probabilities of transition along the given edge
by the time of observation.
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21q as important early leukaemogenic events secondary to the
ETV6/RUNX1 translocation. Later, independent events
include the most common changes in ETV6/RUNX1-positive
childhood ALL patients, such as deletions of 6q, 9p, 13q and X
and amplification of chromosome 10, suggesting these changes
occur later in the development of the leukaemic clone. These
implications need to be confirmed, if possible, in studies
directly observing the sequential order of occurrence of CNAs.
A recent study also demonstrated a similar model with data
from 164 ETV6/RUNX1-positive childhood ALL patients (Lil-
ljebjorn et al, 2010). The authors demonstrated independence
between deletions on 6q, 9p and 12p, however with 6q and 9p
closer to the root. Also amplification of chromosome 21 was
far down a subtree rooting from 6q deletion. However, the
two models cannot be compared directly because the resolu-
tion of analysed aberrations differed between the two studies.
Furthermore, Anderson et al (2011) has also recently per-
formed an oncogenetic tree mapping, however the study only
explored pre-selected CNAs at single cell level in individual
patients. Thus, the results and those from the present study
are not directly comparable, but the nonlinear branching nat-
ure of the sequence of the acquired CNAs is alike.
Finally, we associated recurrent CNAs with miRNAs tran-
scribed in those regions in order to elucidate the conse-
quences on gene regulation of the investigated miRNAs
targets. Here we observed deletions and amplifications in sev-
eral chromosomal regions containing miRNAs known to be
associated with tumourigenecity, leukaemia and regulation of
apoptosis among others (Data S2). Thus, miRNAs may play
a crucial role in childhood ALL by targeting a number of
proteins and affecting various functional pathways.
Even though many clinical trials classify ETV6/RUNX1-
positive childhood ALL as one group, their cytogenetic diver-
sity calls for refinement in the classification of these patients,
which ultimately may lead to a better understanding of their
natural history (including determination of pre- and postna-
tal hits) (Greaves, 2006), the clinical presentation and their
specific treatment requirements. Based on CNAs in protein-
protein complexes, we described four groups of patients. This
analysis could be further refined in the future with a larger
number of samples and higher density arrays.
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